Johann de Bono
Johann de Bono
Adresse e-mail validée de icr.ac.uk - Page d'accueil
Titre
Citée par
Citée par
Année
Abiraterone and increased survival in metastatic prostate cancer
JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ...
New England Journal of Medicine 364 (21), 1995-2005, 2011
41522011
Increased survival with enzalutamide in prostate cancer after chemotherapy
HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R de Wit, ...
New England Journal of Medicine 367 (13), 1187-1197, 2012
39912012
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
PC Fong, DS Boss, TA Yap, A Tutt, P Wu, M Mergui-Roelvink, P Mortimer, ...
New England Journal of Medicine 361 (2), 123-134, 2009
35842009
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
JS De Bono, S Oudard, M Ozguroglu, S Hansen, JP Machiels, I Kocak, ...
The Lancet 376 (9747), 1147-1154, 2010
32222010
Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
25092013
Enzalutamide in metastatic prostate cancer before chemotherapy
TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ...
New England Journal of Medicine 371 (5), 424-433, 2014
24002014
Integrative clinical genomics of advanced prostate cancer
D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ...
Cell 161 (5), 1215-1228, 2015
22792015
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
JS De Bono, HI Scher, RB Montgomery, C Parker, MC Miller, H Tissing, ...
Clinical cancer research 14 (19), 6302-6309, 2008
20972008
DNA-repair defects and olaparib in metastatic prostate cancer
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
15732015
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
13742016
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo …
K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ...
The lancet oncology 13 (10), 983-992, 2012
13112012
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall …
CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ...
The Lancet Oncology 16 (2), 152-160, 2015
10622015
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
10472017
Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostrate cancer commonly remains hormone driven
G Attard, AH Reid, TA Yap, F Raynaud, M Dowsett
Journal of clinical oncology 26 (28), 4563-4571, 2008
9712008
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
PC Fong, TA Yap, DS Boss, CP Carden, M Mergui-Roelvink, C Gourley, ...
Journal of clinical oncology 28 (15), 2512-2519, 2010
9172010
Inherited DNA-repair gene mutations in men with metastatic prostate cancer
CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ...
N Engl J Med 375, 443-453, 2016
8772016
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402, 2016
6762016
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
G Attard, AHM Reid, R A’Hern, C Parker, NB Oommen, E Folkerd, ...
Journal of clinical oncology: official journal of the American Society of …, 2009
6712009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer
G Attard, JF Swennenhuis, D Olmos, AHM Reid, E Vickers, R A'Hern, ...
Cancer research 69 (7), 2912-2918, 2009
6332009
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
HI Scher, X Jia, JS de Bono, M Fleisher, KJ Pienta, D Raghavan, G Heller
The lancet oncology 10 (3), 233-239, 2009
6132009
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20